Advert - Teva – Case AUTH/3656/6/22

Teva was ruled in breach of the following clauses of the 2019 Code for failing to include the black triangle for Ajovy in an article which, in the Panel’s view, Teva was responsible for and was promotional, which was compounded by a failure to include an adverse event reporting statement; for failing to include prescribing information for Ajovy and Copaxone; for failing to certify the article; for describing Copaxone as ‘new’ when it had been available for more than 12 months in the UK, and including a statement in the article which implied that Copaxone was licensed for all types of multiple sclerosis which was not so:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 3.2 - Promoting a medicine in a manner that was inconsistent with the
particulars listed in its summary of product characteristics
Clause 4.1 - Failing to include prescribing information
Clause 4.9 - Failing to include the prominent adverse event reporting statement
Clause 4.10 - Failing to include a black triangle
Clause 7.11 - Referring to a product as ‘new’ when it has generally been available for
more than 12 months in the UK
Clause 9.1 - Failing to maintain high standards
Clause 14.1 - Failing to certify promotional material